Siliq will be cheaper than rivals from Novartis and Eli Lilly.
Pharma begins early intervention trial after Cosentyx shows “disease modifying” properties
Decision paves way for cheaper competitor in autumn 2018.
Guselkumab can also be used if older drug Stellara fails.
But drug will have boxed warning over suicidal ideation.
Celgene continues with focus on autoimmune diseases.
But patents could delay launch for more than a year.
Sales of Humira could peak above $18 billion – CEO
Biotech specialises in autoimmune disorder drugs.